质粒治疗肢体动脉闭塞性疾病的安全性分析  

Safety evaluation on the treatment of periphery artery disease by plasmid

作　　者：毕建进[1] 吴丹莉[1] 张津辉[1] 靳继德[1] 王艳飞[1] 龚萍[1] 王小娜[1] 张庆林[1] 吴祖泽[1] 

机构地区：[1]军事医学科学院放射医学研究所,北京100850

出　　处：《生物技术通讯》2002年第6期443-444,共2页Letters in Biotechnology

基　　金：八六三高技术发展计划项目(2001AA217061)

摘　　要：肢体动脉血管闭塞性病是一种严重危害人类健康的疾病,许多病人最终要截肢,基因治疗为这类患者带来了希望。利用肝细胞生长因子促进血管生成的作用,采用质粒作为载体对大鼠和犬的下肢动脉闭塞疾病模型进行治疗,效果良好。为探讨基因治疗的安全性问题,用绿色荧光蛋白报告基因研究质粒在体内的分布和表达,方法简便。通过制作冰冻切片观察绿色荧光蛋白在小鼠体内的表达情况,发现局部注射质粒不会造成全身性扩散,表明该方法安全。Periphery artery disease(PAD)is a kind of severe disease that leads to amputation in many patients.Gene therapy brings hope to these patients.We used the angiogenesis effect of hepatocyte growth factor to treat the PAD and found the growth of new vessels.But the safety was an important problem of gene therapy.So we investigated the expression and distribution of green fluorescence protein gene as report gene in mice.The conclusion was that plasmids injected locally did not disperse in the body,so gene therapy of PAD with plasmids was safe.

关 键 词：质粒治疗 肢体动脉闭塞性疾病 安全性分析 基因治疗 肝细胞生长因子 

分 类 号：R543.5[医药卫生—心血管疾病] R394.[医药卫生—内科学]